During the past decade, Onkologicky ustav sv. Alzbety, s.r.o. conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 5 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onkologicky ustav sv. Alzbety, s.r.o." #1 sponsor was "Pfizer" with 6 trials, followed by "Central European Cooperative Oncology Group" with 3 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored, "Baxalta now part of Shire" with 1 trials sponsored and "Bayer" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologicky ustav sv. Alzbety, s.r.o." #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Onkologicky ustav sv. Alzbety, s.r.o." are "Breast Cancer" (3 trials), "Early Breast Cancer" (2 trials), "Fever, Sweats, and Hot Flashes" (2 trials), "Infection" (2 trials) and "Leukemia" (2 trials). Many other conditions were trialed in "Onkologicky ustav sv. Alzbety, s.r.o." in a lesser frequency.

Most popular intervention types in "Onkologicky ustav sv. Alzbety, s.r.o." are "Drug" (14 trials), "Biological" (4 trials), "Procedure" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cetuximab" (2 trials), "Encorafenib" (2 trials), "PF-05280014" (2 trials), "5-FU" (1 trials) and "A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment" (1 trials). Other intervention names were less common.

The vast majority of trials in "Onkologicky ustav sv. Alzbety, s.r.o." are 10 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Onkologicky ustav sv. Alzbety, s.r.o.". undefined are not yet recruiting, 5 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Onkologicky ustav sv. Alzbety, s.r.o., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Onkologicky ustav sv. Alzbety, s.r.o., 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".